Bradley Canino
Stock Analyst at Stifel
(2.23)
# 2,795
Out of 5,072 analysts
88
Total ratings
36.71%
Success rate
0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $19.87 | +121.44% | 7 | Sep 10, 2025 | |
| JANX Janux Therapeutics | Reinstates: Buy | $45 | $34.69 | +29.72% | 3 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $3.78 | +296.83% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.38 | +8.70% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $11.74 | +61.84% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $8.03 | +186.43% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $12.42 | +310.63% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $11.99 | +58.47% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $100.35 | -58.15% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $17.82 | +124.47% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $109.15 | +23.68% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $11.82 | +69.20% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.28 | +89.39% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.44 | +594.44% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $96.09 | +3.03% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.68 | +422.39% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $67.86 | -18.95% | 4 | Feb 23, 2024 |
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $19.87
Upside: +121.44%
Janux Therapeutics
Sep 10, 2025
Reinstates: Buy
Price Target: $45
Current: $34.69
Upside: +29.72%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $3.78
Upside: +296.83%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.38
Upside: +8.70%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $11.74
Upside: +61.84%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $8.03
Upside: +186.43%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $12.42
Upside: +310.63%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $11.99
Upside: +58.47%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $100.35
Upside: -58.15%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $17.82
Upside: +124.47%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $109.15
Upside: +23.68%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $11.82
Upside: +69.20%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $5.28
Upside: +89.39%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.44
Upside: +594.44%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $96.09
Upside: +3.03%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.68
Upside: +422.39%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $67.86
Upside: -18.95%